Specific LDL and HDL targets have been replaced with high-intensityStatinif 10 yearCardiovascular Risk>20% High intensityStatin(age <75 years with 10 yearCardiovascular Risk>20%) Rosuvastatin 20-40 mg orally daily Low intensityStatin(age >75 years, orStatinintolerant) ...
Sixty-eight patients were randomly assigned in a 1:1 ratio to receive a combination of low-intensity rosuvastatin (5 mg/day) and ezetimibe (10 mg/day) or high-intensity rosuvastatin (20 mg/day). The primary endpoint was the absolute difference in the HbA1c levels at 12 we...
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr 5; 295(13): 1556–65. Google Scholar Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high...
Rosuvastatin is a single enantiomeric hydroxy acid that is administered as the calcium salt. The drug has a relatively low lipophilicity. Rosuvastatin has a high affinity for the active site of HMG-CoA reductase activity. Inin vitroandin vivostudies, rosuvastatin typically inhibits HMG-CoA reductase...
AHA/ACC considers rosuvastatin 20–40 mg daily to be a high-intensity statin and rosuvastatin 5–10 mg daily to be a moderate-intensity statin.The addition of a nonstatin drug (e.g., ezetimibe, PCSK9 inhibitor) to statin therapy may be considered in certain high-risk patients who require...
Objective To evaluate the effect of colchicine and high-intensity rosuvastatin in addition to standard of care on the progression of COVID-19 disease in hospitalised patients.Design A pragmatic, open-label, multicentre, randomised controlled trial conducted from October 2020 to September 2021. Follow-...
According to recent studies, each 40 mg/dl reduction in LDL cholesterol by statin therapy confers a 20% reduction in ASCVD. In other words, a relative risk reduction of 30% in ASCVD by moderate-intensity therapy and 45% by high-intensity therapy has been approximated. ...
Very high-intensity statin therapy using rosuvastatin 40 mg/day achieved an average LDL-C of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in significant regression of atherosclerosis for all prespecified IVUS measures of disease burden.35 In the same study, blinded quantitative coronary ...
The RACING trial randomized patients with ASCVD who were at very high risk of CVD events to ezetimibe (10 mg/d) plus rosuvastatin (10 mg/d) or rosuvastatin 20 mg/d.47 The combination therapy was non-inferior to high-intensity rosuvastatin monotherapy for the 3-year composite of CVD death,...
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy Article Open access 14 November 2024 References Timmis A, Townsend N, Gale GP, et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12–85...